Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.

The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.

Request To Download Sample of This Strategic Report:-
reportocean.com/industry-verticals/sample-request?report_id=26945

Market Statistics:

The file offers market sizing and forecast throughout 5 primary currencies – USD, EUR GBP, JPY, and AUD. It helps corporation leaders make higher choices when foreign money change records are available with ease. In this report, the years 2020 and 2021 are regarded as historic years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2030 are viewed as the forecast period.

The Centers for Medicare and Medicaid Services report that US healthcare expenditures grew by 4.6% to US$ 3.8 trillion in 2019, or US$ 11,582 per person, and accounted for 17.7% of GDP. Also, the federal government accounted for 29.0% of the total health expenditures, followed by households (28.4%). State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.

The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Get a Request Sample Report:
reportocean.com/industry-verticals/sample-request?report_id=26945

Key benefits

The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
Key market segments
The world COPD and asthma drug market is segmented by medication class, disease and geography.

MARKET BY DISEASES

COPD
Asthma

MARKET BY MEDICATION CLASS

Combination Products
Seretide/Advair
Symbicort
Relvar/Breo Ellipta
Flutiform
Dulera
Others
Leukotriene Antagonists (LTA)
Singulair
Others
Inhaled Corticosteroids (ICS)
Qvar
Pulmicort
Aerospan
Flovent
Others
Anticholinergics
Spiriva
Others
Short Acting Beta Agonists(SABA)
ProAir
Ventolin
Others
Long Acting Beta Agonists (LABA)
Others

Request full Report-
reportocean.com/industry-verticals/sample-request?report_id=26945

MARKET BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa

KEY PLAYERS

GlaxoSmithKline (GSK)
Novartis AG.
Merck & Co.
Abbott Laboratories.
Boehringer Ingelheim.
AstraZeneca.
Roche Holding AG
Teva Pharmaceutical Industries.
Vectura Group
Pfizer

Other players in the value chain include (profiles not included in the report)

Mylan
Aerovance Inc.
Alkermes Inc.
Almirall SA
Genentech Inc.
Sepracor, Inc.
Skyepharma plc

Table of Content:

  • Market Definition and Overview
  • Research Method and Logic
  • Market Competition Analysis
  • Product and Service Analysis
  • Strategies for Company to Deal with the Impact of COVID-19
  • Market Segment by Type, Historical Data and Market Forecasts
  • Market Segment by Application, Historical Data and Market Forecasts
  • Market by by Region, Historical Data and Market Forecasts
  • Market Dynamic Analysis and Development Suggestions

Key Questions Answered in the Market Report

•    How did the COVID-19 pandemic impact the adoption of by various pharmaceutical and life sciences companies?
•    What is the outlook for the impact market during the forecast period 2021-2030?
•    What are the key trends influencing the impact market? How will they influence the market in short-, mid-, and long-term duration?
•    What is the end user perception toward?
•    How is the patent landscape for pharmaceutical quality? Which country/cluster witnessed the highest patent filing from January 2014-June 2021?
•    What are the key factors impacting the impact market? What will be their impact in short-, mid-, and long-term duration?
•    What are the key opportunities areas in the impact market? What is their potential in short-, mid-, and long-term duration?
•    What are the key strategies adopted by companies in the impact market?
•    What are the key application areas of the impact market? Which application is expected to hold the highest growth potential during the forecast period 2021-2030?
•    What is the preferred deployment model for the impact? What is the growth potential of various deployment models present in the market?
•    Who are the key end users of pharmaceutical quality? What is their respective share in the impact market?
•    Which regional market is expected to hold the highest growth potential in the impact market during the forecast period 2021-2030?
•    Which are the key players in the impact market?

Inquire or Share Your Questions If Any Before the Purchasing This Report –reportocean.com/industry-verticals/sample-request?report_id=26945

About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:
Report Ocean:
Email: [email protected]
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website:www.reportocean.com

Source link